NDT Advance Access published online on August 5, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl387
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Dialysis Unit, Eurodial, Leiria, Portugal
* To whom correspondence should be addressed. Background. It is becoming increasingly more common to administer intravenous (i.v.) darbepoetin alfa to haemodialysis (HD) patients at less frequent dosing intervals in routine clinical practice. This study investigated extending the dosing interval for i.v. darbepoetin alfa treatment from once a week (QW) to once every 2 weeks (Q2W) at the same dose in order to maintain target haemoglobin (Hb) concentrations (11-13 g/dl). Methods. Stable HD patients in routine clinical practice receiving i.v. darbepoetin alfa QW for a period of 6 months (n = 105) (treatment period 1) were switched to i.v. Q2W darbepoetin alfa for a further 6 months (treatment period 2) (n = 90). The dose of i.v. darbepoetin alfa was titrated to maintain Hb concentrations between 11 and 13 g/dl throughout the full 12-month study period. Results. The mean change in Hb for treatment period 2 was 0.04 ± 1.1 g/dl (±SD), which was not clinically relevant (11.7 ± 0.8 g/dl vs 11.7 ± 1.0 g/dl; P = 0.8). The mean weekly doses of darbepoetin alfa were similar throughout the treatment periods (34.0 ± 17.1 µg/week vs 32.1 ± 17.3 µg/week; P = 0.3, respectively for QW and Q2W dosing). Intravenous darbepoetin alfa was well tolerated. Conclusions. The treatment of renal anaemia in HD patients with i.v. Q2W darbepoetin alfa effectively and safely maintains Hb concentrations at a less frequent dosing regimen than observed with QW administration. Dose requirements for i.v. darbepoetin alfa administered QW or Q2W were not different. The results of this study demonstrate that i.v. darbepoetin alfa administered Q2W is an effective regimen for HD patients requiring anaemia treatment in routine clinical practice.
Received March 17, 2006
Accepted June 8, 2006
Original Article
The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Fernando Carrera 1 *, Lino Oliveira 1, Pedro Maia 1, Teresa Mendes 1, and Candido Ferreira 1
Fernando Carrera, E-mail: fcarrera{at}mail.telepac.pt
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera and M. Burnier Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations NDT Plus, January 1, 2009; 2(suppl_1): i9 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|